


PHARMACEUTICAL 2022



Cyteir Therapeutics Inc. Rank 39 of 466





PHARMACEUTICAL 2022





Cyteir Therapeutics Inc. Rank 39 of 466

The relative strengths and weaknesses of Cyteir Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cyteir Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Cyteir Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 275%, being 197% points above the market average of 78%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 193,077 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 7,511 |
| Liabilities, Non-Current | 201 |
| Other Assets | 256 |
| Other Compr. Net Income | 0 |
| Other Expenses | 0 |
| Other Liabilities | 384 |
| Other Net Income | 133 |
| Other Revenues | 0 |
| Property and Equipment | 2,055 |
| Research and Development | 30,959 |
| Selling, General and Administrative Expense | 11,300 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 195,388 |
| Liabilities | 8,096 |
| Expenses | 42,259 |
| Revenues | 0 |
| Stockholders Equity | 187,292 |
| Net Income | -42,126 |
| Comprehensive Net Income | -42,126 |
| Economic Capital Ratio | 275% |